Greywolf Therapeutics
Martin Quibell is a seasoned medicinal chemist with over 20 years of industrial experience in the pharmaceutical sector, currently serving as Co-founder and Scientific Advisor at Pandeia Therapeutics since September 2019, where the focus is on GPR88 agonists for Huntington’s disease. Quibell also holds roles as Medicinal Chemistry Lead at Pheno Therapeutics Ltd and Grey Wolf Therapeutics, where efforts are directed towards therapeutic innovations. Additionally, Quibell is the Founder and Director of Pedanius Therapeutics Limited and has a longstanding position as Director at MAQU Chemistry Consulting. Previous positions include Consultant Principal Chemist at Mission Therapeutics, Director of Chemistry at Sygnature Discovery Limited, and Senior Director at Shire Pharmaceuticals. Quibell's extensive contributions to drug discovery are backed by over 50 scientific publications and more than 30 patent applications. Educational qualifications include a PhD in Solid Phase Chemistry from the University of Birmingham.
This person is not in the org chart
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.